

Data Sharing Statement

Unger. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma. *JAMA Oncol.* Published November 23, 2022. doi:10.1001/jamaoncol.2022.5486

Data

Data available: Yes

Data types: Deidentified participant data, Data dictionary

How to access data: Data pertinent to this analysis will be made available upon request for researchers whose proposed use of the data has been approved by the SWOG Cancer Research Network.

When available: beginning date: 01-01-2023

Supporting Documents

Document types: None

Additional Information

Who can access the data: researchers whose proposed use of the data has been approved

Types of analyses: for any purpose

Mechanisms of data availability: after approval of a proposal and with a signed data use agreement